Cure CMD Collaborates with MDA and Cure ADSSL1 to fund Beggs Lab for SELENON Research

Progress in neuromuscular research depends on collaboration — researchers, families, advocates, and organizations coming together to accelerate treatment development.

Cure CMD is thrilled to share a partnership with the Muscular Dystrophy Association and

Boston Children’s Hospital, home to the Beggs Laboratory, where researchers are advancing SELENON-related myopathy research supported by Cure CMD, MDA, and Cure ADSSL1.

Cure ADSSL1 to fund a research project for the Beggs Laboratory at Boston Children’s Hospital.

This project will use next-generation genomic tools and AAV-based gene therapies to uncover disease mechanisms and develop treatments for SELENON-Related Myopathy.

Sharon Hesterlee, PhD, President and CEO at MDA: “By combining resources and expertise with our colleagues at disease-specific organizations, we can fund more innovative projects and accelerate the development of treatments that have the greatest potential to change lives.”

Priyanka Kakkar, President for Cure ADSSL1: “For patient-founded organizations like ours, collaboration is the most powerful accelerator.”

Rachel Alvarez, Executive Director for Cure CMD: “We are thrilled to partner with Cure ADSSL1 and the MDA to fund this important work. Collaboration is critical to advancing rare neuromuscular disease research toward treatments.”

___________________________________________________________________________________

Learn more about Cure CMD's research strategy and funding portfolio. Want to support vital research? Make a donation today.